# TB-500 – 10mg/vial (Research Use Only)

### BPC-157, TB-500 & GHK-Cu: What’s the Difference?

Six related products, in two formats. Here’s what’s actually in each one.

| Product | Contains | Format | Price |
| --- | --- | --- | --- |
| BPC-157 (injectable) | BPC-157 only | Injectable vial, 10mg | $56.00 |
| BPC-157 (capsules) | BPC-157 only | 100 capsules, 500mcg each | $155.00 |
| TB-500 | TB-500 only | Injectable vial, 10mg | $72.00 |
| BPC-157 + TB-500 | BPC-157 + TB-500 (5mg + 5mg) | Injectable vial, 10mg total | $69.00 |
| BPC + TB Capsules | BPC-157 + TB-500 (500mcg + 500mcg) | 100 capsules, 1,000mcg total each | $94.05 |
| GLOW-70 | GHK-Cu + TB-500 + BPC-157 (50mg + 10mg + 10mg) | Injectable vial | $112.00 |

**GLOW-70 vs. standalone GHK-Cu – the question we get most:** GHK-Cu (sold on its own as a 100mg vial, $49.00) is a single copper-binding peptide. GLOW-70 is a different, separate product: a blended vial that combines GHK-Cu with two other peptides, TB-500 and BPC-157, in one injection (50mg + 10mg + 10mg). If you’re comparing the two, the real question is single-compound vs. a three-compound blend – GLOW-70 is not just “more GHK-Cu,” it’s GHK-Cu plus two additional peptides in the same vial.

Backed by the Research [Read: TB-500 (Thymosin Beta-4): What the Research Explores →](https://portaltowellness.net/research/tb-500-thymosin-beta-4-research/)

### Overview

TB-500 occupies a unique position at the intersection of cytoskeletal dynamics, cellular migration, and tissue remodeling research. As the synthetic analogue of the biologically active actin-binding domain of Thymosin Beta-4 (Tβ4) — one of the most abundant intracellular peptides in the mammalian body — TB-500 has generated sustained investigative interest across multiple published research disciplines, from wound biology to cardiac repair models.

### What It Is

TB-500 is a synthetic 17-amino acid peptide representing the central actin-sequestering motif of Thymosin Beta-4 (Tβ4), the endogenous 43-amino acid protein (MW ~4,964 Da) encoded by the TMSB4X gene and expressed in virtually all mammalian cell types. This fragment retains the G-actin binding functionality of the parent molecule and has been the focus of published research since Tβ4 was first characterized in thymic tissue. TB-500’s molecular weight is approximately 2,024 Da.

### Research Spotlight

The published research base for TB-500 and its parent molecule Thymosin Beta-4 is extensive. Foundational cell biology research established Tβ4’s role in G-actin sequestration and its critical function in regulating cytoskeletal dynamics, cell motility, and wound repair initiation. In vitro studies using scratch assay and transwell migration systems have examined keratinocyte, fibroblast, and endothelial cell responses to TB-500 administration — mechanistic work that has informed a broad investigative pipeline.

In vivo preclinical research in rodent models has examined tissue-level responses to TB-500 in musculoskeletal, dermal, and cardiac contexts, with histological and biomechanical endpoints documented across multiple publications. Cardiac research has examined cardiomyocyte survival markers and coronary vasculogenesis parameters in post-ischemic animal models. Anti-inflammatory pathway research has investigated TB-500’s modulation of NF-kB signaling and inflammatory cytokine profiles in relevant in vivo preparations.

### Key Research Applications

- Cytoskeletal G-actin sequestration and cell motility studies
- In vitro wound healing assays (scratch, transwell migration models)
- Musculoskeletal tissue repair and biomechanical endpoint research
- Cardiac tissue modeling and cardiomyocyte survival marker studies
- Coronary vasculogenesis and angiogenesis research
- NF-kB pathway and anti-inflammatory mechanism investigations
- Pharmacokinetic and half-life characterization in animal models
- Combination studies with GHRH analogues (CJC-1295 pairing research)

### Purity & Quality

Portal to Wellness TB-500 is lyophilized to ≥98% purity (supplier specification). Each 10mg vial is suitable for laboratory-scale research and is shipped with cold-chain integrity.

### Competitor Research Notes

Key differentiation points when comparing TB-500 sources: HPLC purity documentation (≥98% is the research-standard benchmark), peptide sequence verification via mass spectrometry, and proper lyophilization and storage conditions. Vial size and price-per-mg should be compared against verified purity levels, not just unit cost.

### Technical Specifications

| Amino Acids | 17 (active actin-binding fragment of Tβ4) |
| --- | --- |
| Molecular Weight | ~2,024 Da |
| Parent Peptide | Thymosin Beta-4 (TMSB4X gene product) |
| CAS Number | 77591-33-4 (TB-500 fragment) |
| Purity | ≥98% (supplier specification) |
| Form | Lyophilized powder |
| Vial Size | 10mg |
| Storage | −4 °F long-term |

**FOR RESEARCH USE ONLY.** Not intended for human or veterinary consumption, medical diagnosis, treatment, or prevention of any disease or condition. This product has not been evaluated by the FDA or any regulatory agency. Must be handled by qualified research personnel in a compliant laboratory setting. These statements have not been evaluated by the Food and Drug Administration.

Not sure which compounds fit your research? [Browse the Research Hub →](https://portaltowellness.net/research/)

### Related research (educational)

- [Overlapping Pathways in Circadian, Repair and Mitochondrial Biology](https://portaltowellness.net/research/sleep-repair-energy-one-system/)
- [TB-500 (Thymosin Beta-4): What the Research Explores](https://portaltowellness.net/research/tb-500-thymosin-beta-4-research/)
- [Recovery & Repair Research Compounds: A Complete Guide](https://portaltowellness.net/research/recovery-repair-research-compounds-guide/)

Regulatory Status Note

On July 23–24, 2026, FDA’s Pharmacy Compounding Advisory Committee reviewed whether BPC-157, TB-500, KPV, MOTS-c, Semax, Epitalon, and emideltide (DSIP) should be added to the 503A Bulks List for pharmacy compounding. The committee voted to recommend six of the seven; emideltide (DSIP) was **not** recommended. FDA’s own briefing documents had recommended against all seven.

A committee vote is a recommendation only. It does not constitute FDA approval, does not establish safety or effectiveness, and does not change the status of this product, which is sold strictly for research use. FDA must complete formal rulemaking before any substance is added to the list. [Source: FDA Advisory Committee Calendar](https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026) . Last reviewed: August 17, 2026.

**Update — July 24, 2026:** On July 23, the committee voted. BPC-157, KPV, and TB-500 each passed 8-6 with one abstention; MOTS-c passed 7-5 with two abstentions. The recommendation is non-binding — FDA is not required to follow it, must still issue a formal decision, and the process may require additional rulemaking before any compounding pharmacy could act on it. No peptide has been FDA-approved, and this update does not constitute or imply a therapeutic claim. [Source: STAT News](https://www.statnews.com/2026/07/23/fda-panel-okays-peptides-compound-pharmacies-bpc-157-kpv/)

At a Glance: Four Separate Questions

- **Research status:** Sold for research/laboratory use only, not as a consumer drug.
- **Compounding status:** An FDA advisory committee recommended possible inclusion on the 503A Bulks List (non-binding). FDA has not issued a final decision.
- **FDA approval status:** Not FDA-approved for any use.
- **Evidence status:** Preclinical/animal research on cell migration and tissue repair; WADA-prohibited in competitive sport; no completed human clinical trials have established safety or efficacy.

Last reviewed: August 9, 2026 — status unchanged (still an advisory committee recommendation; not final 503A inclusion or FDA approval). See our [full explainer on these four categories](https://portaltowellness.net/research/compounded-peptide-vs-research-peptide/) .

---

Source: https://portaltowellness.net/shop/tb500-10mg/
Research use only. Terms: https://portaltowellness.net/research-use-only/